Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma

BACKGROUND: First-line treatment for metastatic renal cell carcinoma (mRCC) is rapidly changing. It currently includes VEGF targeted therapies (TT), multi-target tyrosine kinase inhibitors (TKIs), mTOR inhibitors, and immunotherapy. To optimize outcomes for individual patients, genomic markers of re...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS One
Hlavní autoři: Stenehjem, David D., Hahn, Andrew W., Gill, David M., Albertson, Daniel, Gowrishankar, Banumathy, Merriman, Joseph, Agarwal, Archana M., Thodima, Venkata, Harrington, Erik B., Au, Trang H., Maughan, Benjamin L., Houldsworth, Jane, Pal, Sumanta K., Agarwal, Neeraj
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6347137/
https://ncbi.nlm.nih.gov/pubmed/30682039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0210415
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky